";s:4:"text";s:4850:"You may report side effects to FDA at 1-800-FDA-1088.Tell your doctor about all your other medicines, especially:This list is not complete.
In transplant patients, however, reduced immunosuppression may place the graft at risk. It can be given by mouth or by injection into a vein.
Monitoring infected patients for clinical and laboratory signs of active HBV or HCV infection is recommended.Cases of pure red cell aplasia (PRCA) have been reported in patients treated with MPA derivatives in combination with other immunosuppressive agents.
If you would like more information, talk with your doctor. The simultaneous administration of any of the following drugs with Myfortic may result in clinically significant adverse reactions:In a 104-week oral carcinogenicity study in rats, mycophenolate sodium was not tumorigenic at daily doses up to 9 mg per kg, the highest dose tested.
This is in large part due to the high plasma protein binding of mycophenolic acid.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Patients with a BSA of >1.58 m² may be dosed either with four Myfortic 180 mg tablets, or two Myfortic 360 mg tablets twice daily (1440 mg daily dose). This decrease is consistent with interruption of enterohepatic recirculation which may be due to binding of recirculating MPAG with cholestyramine in the intestine [seeConcomitant administration of sevelamer and MMF in stable adult and pediatric kidney transplant patients decreased the mean MPA Cmax and AUC(0-12h) by 36% and 26% respectively [seeCyclosporine (Sandimmune®) pharmacokinetics (at doses of 275 to 415 mg/day) were unaffected by single and multiple doses of 1.5 grams twice daily of MMF in 10 stable kidney transplant patients. Mycophenolic acid (Myfortic) and mycophenolate mofetil (CellCept - a similar medicine also used to help the body from harming an organ after an organ transplant) are not absorbed equally in the body. Mycophenolate mofetil capsules may be given at dose of 750 mg PO twice daily for children with a body surface area (BSA) of 1.25 to 1.5 m2 or 1 g PO twice daily for children with a BSA > 1.5 m2.
At month 12 post-transplant, the mean MPA (AUC(0-12h)) in the cyclosporine withdrawal group was approximately 40% higher, than that of the standard dose cyclosporine group.Cyclosporine inhibits multidrug-resistance-associated protein 2 (MRP-2) transporter in the biliary tract, thereby preventing the excretion of MPAG into the bile that would lead to enterohepatic recirculation of MPA [seeFollowing single-dose administration of MMF (1 g) to 11 healthy volunteers on day 4 of a 5-day course of a combination of norfloxacin and metronidazole, the mean MPA AUC(0-48h) was reduced by 33% compared to the administration of MMF alone (p<0.05). However, in the early post-transplant period, mean MPA AUC and Cmax were approximately one-half of those measured 6 months post-transplant.After near equimolar dosing of Myfortic 720 mg twice daily and MMF 1000 mg twice daily (739 mg as MPA) in both the single-and multiple-dose cross-over trials, mean systemic MPA exposure (AUC) was similar.No specific pharmacokinetic studies in individuals with renal impairment were conducted with Myfortic.
Although dialysis may be used to remove the inactive metabolite MPAG, it would not be expected to remove clinically significant amounts of the active moiety MPA.
MPAG is also secreted in the bile and available for deconjugation by gut flora. Patients with increased risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor. However, based on studies of renal impairment with MMF, MPA exposure is not expected to be appreciably increased over the range of normal to severely impaired renal function following Myfortic administration.In contrast, MPAG exposure would be increased markedly with decreased renal function; MPAG exposure being approximately 8-fold higher in the setting of anuria. Mean (±SD) ganciclovir AUC and Cmax (n=10) were 54.3 (±19.0) mcg•h/mL and 11.5 (±1.8) mcg/mL, respectively, after coadministration of the two drugs, compared to 51.0 (±17.0) mcg•h/mL and 10.6 (±2.0) mcg/mL, respectively, after administration of intravenous ganciclovir alone. Especially tell your doctor if you take:Know the medicines you take. In some cases, PRCA was found to be reversible with dose reduction or cessation of therapy with MPA derivatives.